The present invention is directed to the use of a Apelawa variety of quinoa in the production of cytoplasmic male sterile quinoa plants and seeds useful in breeding programs for high-yield quinoa hybrids. More particularly, the present invention is directed to the use of cytoplasmic male sterile plants of the Apelawa variety of quinoa to produce plants and seeds for lines of quinoa varieties having male sterile cytoplasm; to cytoplasmic male sterile quinoa plants; quinoa seeds for cytoplasmic male sterile plants; and methods of producing cytoplasmic male sterile quinoa plants and seeds to create a source of cytoplasmic male sterile quinoa plants. A quinoa seed having male sterile cytoplasm and assigned ATCC accession no. 75154 is specifically disclosed.
The invention relates to novel inbred rice lines designated A0044 and B0044, and the plants of inbred rice lines A0044 and B0044 as well as the rice plant and plant parts produced by the seed designated A0044. The invention also relates to methods of maintaining the male-sterile line A0044 by crossing it with the fertile line B0044 and to methods of producing hybrid rice plants by crossing inbred rice line A0044 with rice lines that act as pollen parents to restore fertility to the F.sub.1 plants. Further, the invention relates to hybrid rice plants in which inbred rice line A0044 is the female parent.
The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the deletion of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
